Cargando…
Real-World Switching to Riociguat: Management and Practicalities in Patients with PAH and CTEPH
PURPOSE: A proportion of patients with pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) do not achieve treatment goals or experience side effects on their current therapy. In such cases, switching patients to a new drug while discontinuing the first may...
Autores principales: | Gall, Henning, Vachiéry, Jean-Luc, Tanabe, Nobuhiro, Halank, Michael, Orozco-Levi, Mauricio, Mielniczuk, Lisa, Chang, MiKyung, Vogtländer, Kai, Grünig, Ekkehard |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5942346/ https://www.ncbi.nlm.nih.gov/pubmed/29470642 http://dx.doi.org/10.1007/s00408-018-0100-3 |
Ejemplares similares
-
Initial Riociguat Monotherapy and Transition from Sildenafil to Riociguat in Patients with Idiopathic Pulmonary Arterial Hypertension: Influence on Right Heart Remodeling and Right Ventricular–Pulmonary Arterial Coupling
por: Taran, Irina N., et al.
Publicado: (2018) -
Switching to riociguat: a potential treatment strategy for the management of CTEPH and PAH
por: Benza, Raymond L., et al.
Publicado: (2020) -
Switching from sildenafil to riociguat for the treatment of PAH and inoperable CTEPH: Real-life experiences
por: Andersen, Asger, et al.
Publicado: (2017) -
Riociguat dose titration in patients with chronic thromboembolic pulmonary hypertension (CTEPH) or pulmonary arterial hypertension (PAH)
por: Ghofrani, Hossein A, et al.
Publicado: (2009) -
Haemodynamic effects of riociguat in CTEPH and PAH: a 10-year observational study
por: Yang, Suqiao, et al.
Publicado: (2021)